News | July 05, 2023
Syngene to acquire multi-modal facility from Stelis Biopharma
Adding 20,000 liters of installed biologics drug substance manufacturing capacity
Adding 20,000 liters of installed biologics drug substance manufacturing capacity
Specialty Chemicals grew 38% YoY for FY23
Revenue from operations at Rs 512.81 crores registered a growth of 17% Y-o-Y for full year FY23
The top 15 Indian pharma players have continued to experience anaemic growth in the US market over the five years ended FY22
Advent will also be making an open offer to acquire additional 26% of the outstanding equity shares of the company from the public shareholders.
Within the API segment, ~20% of the revenues came from the domestic market and ~80% from the exports market
The company hopes to build on this momentum in the coming quarters and continue to focus on our key brands to drive sustainable profitable growth
Revenue from operations up 26% to Rs. 768 crores
In Q2 FY23, the overall performance of the company continued to be strong despite the ongoing geo-political challenges impacting supply chain and costs
The company will strengthen its position in the ‘green solvent’ market by increasing its capacity by 20% to 120,000 MTPA from 100,000 MTPA before the end of current fiscal
Subscribe To Our Newsletter & Stay Updated
